Injective Breakout — Buy on Weakness After 9% Surge

I see Injective rallying to $16.39, up about 9% after the team unveiled a new financial primitive.

The move cleared key resistance and shows fresh bullish momentum, but the RSI is approaching overbought territory, which raises the chance of a short-term pullback.

I would prefer to wait for consolidation or a retest of the breakout area before materially increasing exposure; momentum traders can take partial positions with tight risk controls.